The scientific and clinical basis for the treatment of Parkinson disease (2009)
Olanow et al.
Neurology 2009;72:S1-S136.
ABSTRACT
| FULL TEXT
The Liver Toxicity Biomarker Study: Phase I Design and Preliminary Results
McBurney et al.
Toxicol Pathol 2009;37:52-64.
ABSTRACT
| FULL TEXT
Safety and tolerability of adjunctive tolcapone treatment in patients with early Parkinson's disease
Lees et al.
J. Neurol. Neurosurg. Psychiatry 2007;78:944-948.
ABSTRACT
| FULL TEXT
Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.
Pahwa et al.
Neurology 2006;66:983-995.
ABSTRACT
| FULL TEXT
ASSESSMENT OF CATECHOL INDUCTION AND GLUCURONIDATION IN RAT LIVER MICROSOMES
Elovaara et al.
Drug Metab. Dispos. 2004;32:1426-1433.
ABSTRACT
| FULL TEXT
Drug-Induced Hepatotoxicity
Lee
NEJM 2003;349:474-485.
FULL TEXT
Parkinson's disease and anaesthesia
Nicholson et al.
Br J Anaesth 2002;89:904-916.
ABSTRACT
| FULL TEXT
Frontiers in Neuropharmacotherapy Part II: Multiple Sclerosis and Parkinson's Disease
Chappell and Cohen
Journal of Pharmacy Practice 2002;15:221-240.
ABSTRACT
An algorithm (decision tree) for the management of Parkinson's disease (2001):: Treatment
Olanow et al.
Neurology 2001;56:S1-S88.
FULL TEXT
Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.
Pahwa et al.
Neurology 2006;66:983-995.
ABSTRACT
| FULL TEXT